EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania

Elada Indrisiunaite, Ieva Renata Jonaityte iD, Tatjana Karmaziene, Tadas Raudonis iD

Medicina · 30.04.2026 · 62 (5) · 855

DOI: 10.3390/medicina62050855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, online erschienen am 30.04.2026. Verfasst von Elada Indrisiunaite und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Vilnius University, M. K. Čiurlionio g. 21, 03101 Vilnius, Lithuania. Hauptthemen laut MEDLINE: Psoriasis, Biological Therapy. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Biological therapy is widely used to treat moderate-to-severe psoriasis. This study aimed to assess the real-world effectiveness and drug survival of biologic treatment in patients with moderate-to-severe psoriasis. Materials and Methods: A retrospective study of 210 patients with moderate-to-severe psoriasis who were treated with biological therapy between 2018 and 2023 was conducted. Baseline data included demographics, comorbidities, prior treatments, Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores, laboratory results, current psoriasis treatment, and treatment-related adverse events.

Results

Of the 210 patients, 60.0% were male (n = 126). The mean age was 48.3 ± 13.6 years in men (range 16–74) and 48.4 ± 13.6 years in women (range 17–79). The mean PASI at initiation of biologic therapy was 15.0 ± 8.1 and decreased to 3.3 ± 4.7 at 1 year, 2.7 ± 4.0 at 3 years, and 2.8 ± 3.3 at 5 years. Drug discontinuation differed between therapies: etanercept had a higher hazard of discontinuation than ustekinumab (hazard ratio (HR) 2.55, 95% confidence interval (CI) 1.17–5.52; p = 0.0179), infliximab (HR 0.36, 95% CI 0.13–0.97; p = 0.0429) and adalimumab (HR 0.47, 95% CI 0.23–0.98; p = 0.0453).

Conclusions

In routine clinical practice, biologic therapy was associated with substantial and sustained improvements in the PASI over up to 5 years of follow-up. Drug survival was initially high for all agents but separated over time, with etanercept showing the poorest long-term persistence and a higher hazard of discontinuation compared with other drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological TherapyHumansMiddle AgedFemaleLithuaniaMaleAdultRetrospective StudiesAgedSeverity of Illness IndexAdolescentEtanerceptTreatment OutcomeYoung AdultUstekinumabAdalimumabQuality of Life

Stichwörter der Autor:innen

DLQIPASIbiological therapydrug survivalefficacypsoriasis

Substanzen

EtanerceptUstekinumabAdalimumab

Autor:innen und Institutionen

  • Faculty of Medicine, Vilnius University, M. K. Čiurlionio g. 21, 03101 Vilnius, Lithuania.
  • Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. Čiurlionio g. 21, 03101 Vilnius, Lithuania.

ORCID-Profile: Ieva Renata Jonaityte, Tadas Raudonis

Zitieren

APA

Indrisiunaite, E., Jonaityte, I. R., Karmaziene, T., & Raudonis, T. (2026). Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania. Medicina, 62(5), 855. https://doi.org/10.3390/medicina62050855

Vancouver

Indrisiunaite E, Jonaityte IR, Karmaziene T, Raudonis T. Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania. Medicina. 2026;62(5):855. doi:10.3390/medicina62050855

BibTeX
@article{Indrisiunaite2026,
  author = {Indrisiunaite, Elada and Jonaityte, Ieva Renata and Karmaziene, Tatjana and Raudonis, Tadas},
  title = {Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {5},
  pages = {855},
  doi = {10.3390/medicina62050855}
}
Kostenlos starten →